Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.62
EPS est.
$-0.08
EPS surprise
-675.00%
1-day move
-7.40%
ImmunityBio, Inc. reported a significant loss per share of $0.62, which contributed to a 7.4% decline in stock price following the announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. Overall, the results indicate challenges for the company in the current fiscal quarter.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | -675.00% |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, and the analysis is based solely on numerical results.
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases. Operating in the health care sector, it aims to harness the body's immune system to fight diseases, which is a significant theme in modern medicine.
Last quarter
In the last quarter, ImmunityBio reported an EPS of -$0.06, beating expectations by 25%. The stock reacted positively, increasing by nearly 13% the following day.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-90.29%
Avg 1-day reaction
-0.30%
Overall, expectations for ImmunityBio are mixed as the company has shown a history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.
Bull case
The optimistic view is that ImmunityBio will continue its trend of beating EPS estimates, potentially leading to a significant stock price increase.
Bear case
On the other hand, if the company fails to provide clear revenue growth or guidance, it could lead to a negative reaction from investors.
The print will turn on these.
Q1
What will the EPS be for Q1-2026?
The EPS figure will be closely watched as it can indicate the company's profitability and influence investor sentiment.
Q2
Will there be any guidance on revenue growth?
Clear revenue guidance is crucial for assessing the company's future prospects and could significantly impact stock performance.
—
Est. EPS
$1.57
Est. Rev
$464M
Impl. Move
±7.2%
Why consensus could be wrong
The Street may be underestimating the potential for ImmunityBio to exceed EPS expectations based on its recent performance trends.
Supporting evidence
The company has beaten EPS estimates in 63% of the last 8 quarters.
Options are pricing a 14.16% move, suggesting significant volatility that may not align with historical performance.
Key risk
If the EPS comes in above -$0.06, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The core thesis revolves around the company's ability to maintain its trend of beating EPS estimates while providing clear revenue guidance.
Bull confirmed if
A positive EPS surprise of more than 25% would confirm the bull case.
Bear confirmed if
An EPS miss below -$0.10 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±14.16%
Historical Avg
±7.9%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±7.7% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.
ATM IV
1.3%
30d HV
92.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.1M
106,056 sh
2 insiders
Net
$1.1M
Net selling
Most Active Insiders· 2 open-market trades
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ImmunityBio beats EPS expectations, history suggests the stock could rise by around 1.68% on average.
In line / cautious
If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction.
Miss
If the company misses EPS estimates, history suggests a potential drop of about 4.38%.
The lines on the call that would change the story.
$851,088.00
Net selling
$268,760.00
Net selling
Recent Transactions
Oct 2, 2026 · @ $10.50
81,056 sh
$851,088.00
Oct 5, 2026 · @ $10.75
25,000 sh
$268,760.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.